SCHEMBL23934211

SCHEMBL23934211

Nc1cc(NC(=O)c2cccc(Br)c2)cc2c1C(=O)NC2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.54
RXFP1 Q9HBX9 1/20 0.53
CA12 O43570 3/20 0.53
CA2 P00918 3/20 0.53
CA9 Q16790 3/20 0.53
CA7 P43166 2/20 0.53
CA1 P00915 2/20 0.53
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.46
POLB P06746 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
CASP3 P42574 4/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
ALDH1A1 P00352 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923273 0.88 RXFP1 (0.55) BRAFRXFP1CA12CA2CA9
SCHEMBL23934277 0.86 KMT2A (0.49) RXFP1KMT2AMEN1POLBCTDSP1
SCHEMBL23934221 0.86 CASP3 (0.60) RXFP1CA12CA2CA9KMT2A
SCHEMBL27100057 0.82 CA12 (0.49) BRAFRXFP1CA12CA2CA9
SCHEMBL23923268 0.82 CASP3 (0.67) RXFP1KMT2AMEN1POLBCASP3
SCHEMBL23934210 0.81 KMT2A (0.51) RXFP1CA12CA2CA9CA1
SCHEMBL23934209 0.80 RXFP1 (0.47) BRAFRXFP1KMT2AMEN1POLB
SCHEMBL23934296 0.80 KMT2A (0.48) RXFP1KMT2AMEN1POLBSMN1; SMN2
SCHEMBL23934217 0.78 JAK2 (0.45) RXFP1KMT2AMEN1POLBCTDSP1
SCHEMBL23934203 0.77 POLB (0.54) RXFP1KMT2AMEN1POLBCTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 BRAF 357/4885RXFP1 2817/4885CA12 4718/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 BRAF 357/4885RXFP1 2817/4885CA12 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.